Background: Neuropsychiatric symptoms (NPs) have been reported with dolutegravir use. We hypothesized that increasing dolutegravir trough concentrations (C trough ) and/or polymorphism in the SLC22A2 gene, encoding the organic cation transporter-2 (OCT2), which is involved in monoamine clearance in the CNS and is inhibited by dolutegravir, might be associated with NPs.
Introduction
Modern combination ART (cART) is characterized by effective, safe and compact regimens that are associated with long-term benefits in people living with HIV; nonetheless, during the first 12 months up to 20% of patients switch their initial therapy for tolerability reasons. 1 International guidelines recommend integrase strand-transfer inhibitors (INSTIs) as first-line options in combination with two NRTIs.
2,3 Despite excellent safety, since the approval of raltegravir, INSTIs have been variably associated with the onset of neuropsychiatric symptoms (NPs), including anxiety, sleep disturbances and headache. [4] [5] [6] Dolutegravir, the most recently approved INSTI, has been specifically studied in this setting. In Phase III clinical trials no excess of NPs was observed, with the exception of the SINGLE study: despite several relevant benefits insomnia was more commonly reported in the dolutegravir (10%) than in the efavirenz arm (7%). 7 After the drug was licensed, several cohort studies suggested a higher rate of discontinuation owing to NPs in patients receiving dolutegravir compared with elvitegravir or raltegravir; the highest rate was 13.7% in a Dutch study and adverse events included sleep disturbances (5.6%), fatigue and headache (4.3%), gastrointestinal complaints (3.8%) and NPs (2.5%, including depression, anxiety, agitation, emotional instability and one case of psychosis). [8] [9] [10] However, other studies, including large cohorts from Europe and the USA, did not confirm such observations and discontinuation rates were significantly lower. [11] [12] [13] Beyond the controversies on the exact incidence of NPs in dolutegravir-receiving patients, several risk factors have been reported, including female gender, older age and abacavir coadministration. A higher dolutegravir exposure was associated with NPs in one study, but this was not confirmed in another cohort study. 14, 15 In a recent case report, a reduced dolutegravir dose (50 mg every other day) and exposure in a female patient with low BMI led to prompt resolution of her symptoms (dizziness, fatigue, insomnia and restlessness). 16 Notably, age and female gender have been associated with higher dolutegravir plasma concentrations; a recent study comparing dolutegravir 24 h exposure in younger and older patients reported higher maximal concentrations and shorter sleep duration in those aged .60 years. 17 Given the variability in NP incidence and severity, we aimed to investigate whether genetic predisposition may partially explain this phenomenon. In particular we focused on the role of an SNP in the SLC22A2 gene, which encodes organic cation transporter 2 (OCT2), since dolutegravir has been shown to inhibit OCT2 function at clinically observed concentrations. Besides being expressed in renal tubular cells, OCT2 is broadly spread in the CNS, where it has been localized in neuronal cell bodies and presynaptic membranes, and at the choroid plexus, where it is involved in the transport of a variety of intrinsic compounds (such as monoamine, dopamine, serotonin, histamine, creatinine and choline). 18, 19 In mice, OCT2 was found to be expressed in the limbic system and to be involved in anxiety-and depression-related behaviours. In addition, genetic deletion of SLC22A2 produced a significant reduction in brain tissue concentrations of norepinephrine and serotonin and was shown to affect long-term response to treatment with antidepressants. 20 
Patients and methods

Study population
A cross-sectional study was performed by enrolling HIV-positive patients from two clinical centres, treated with a dolutegravir-containing regimen for at least 30 days and evaluated during the scheduled follow-up visit. Individuals underwent blood sampling for the determination of allelic discrimination for the SLC22A2 808 C ! A SNP and evaluation of dolutegravir trough concentrations (C trough ). On the same day, a battery of tests was administered to investigate current NPs. These included the self-report Symptom Checklist (SCL)-90-R exploring 10 psychiatric dimensions (somatization, obsessive-compulsive disorder, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, psychoticism and sleep disorders), 21 as well as an ad hoc self-reported questionnaire (investigating different symptoms occurring during the previous 4 weeks, including headache) and the Mini-International Neuropsychiatric Interview Plus subscale. 22 
Ethics
The study was conducted in compliance with the Declaration of Helsinki and local review board regulations; all patients gave written informed consent before blood sampling and questionnaire administration. The study was approved by the local ethics committee (protocol number 7768/16).
Neuropsychiatric scores
Each of the 10 subscales of SCL-90-R comprises 6-13 items, and the scores of each dimension are calculated as the mean of the scores (from 0 to 4 on the basis of increasing intensity) of all the items included, which refer to symptoms reported in the last week. Moreover, a global severity index (GSI) is computed as the average score of all 90 items. According to the Italian adaptation of SCL-90-R, 23 a GSI score .1 indicates a pathological neuropsychiatric performance. This cut-off value was therefore used for GSI as well as for each subscale to indicate pathological values of single neuropsychiatric dimensions.
From the self-reported symptom questionnaire, only the information about the presence of headache during the previous 4 weeks was used for the present study. Self-reported headache was classified in two categories: absent/mild or moderate/severe.
Finally, the Mini-International Neuropsychiatric Interview Plus subscale for suicide risk was administered by a specialized neuropsychologist to explore the presence of current suicidal ideation or recent suicide attempts.
Pharmacokinetics and pharmacogenetics
Plasma samples were collected before the administration of the next dose of cART (C trough ). Dolutegravir concentrations were measured in plasma using a validated HPLC/MS method, with a limit of detection of 16 ng/mL. 24 For samples collected at times different from 24 h since last drug intake, C trough was calculated by the following formula:
where C is the measured concentration and h is time after drug intake; 19 h was used as dolutegravir half-life.
Whole blood was stored at #20 C for pharmacogenetic analysis. Genomic DNA was extracted using a QIAamp whole Blood Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. SLC22A2 808 (rs316019) C ! A polymorphism genotyping was conducted by realtime PCR-based allelic discrimination with the use of standard methods (LightCycler 96, Roche, Monza, Italy). Primers, probes and PCR conditions are available on request (TaqMan SNP Genotyping Assays, ThermoFisher, Monza, Italy).
Statistical analysis
The objective of the study was to investigate the potential association of dolutegravir C trough and SLC22A2 gene variants with NPs.
A descriptive analysis was performed to explore demographic and clinical characteristics of the study population. First, the prevalence of NPs in persons showing different SLC22A2 808 genotypes and increasing dolutegravir C trough was compared using parametric or non-parametric tests, as appropriate. The independent effects of dolutegravir C trough and SLC22A2 SNP on all single neuropsychiatric dimensions were explored using univariate logistic regression (considering neuropsychiatric dimensions as dichotomous outcomes, as previously stated) and, in a secondary analysis, by linear regression (considering neuropsychiatric scores as continuous variables). For dependent variables that were found to be associated with SLC22A2 polymorphism and/or with dolutegravir plasma levels, multivariate models were built by adjusting for every other clinical variable that was found to be associated with the outcome (at P values ,0.100) in univariate analysis and for potential confounders. Hypothesizing an association of active psychiatric disease (APD) with both OCT2 expression 18 and the risk of reporting NPs, this variable was treated as a potential confounder in multivariate models that included SLC22A2 CA genotype as the exposure variable. Age and gender are recognized risk factors for dolutegravir discontinuation owing to NPs; 7 moreover, both older age and female sex are associated with increased dolutegravir C trough . 9, 16 These variables were therefore considered as confounders in multivariate models including dolutegravir as an exposure variable. Finally, considering the role of certain concomitant antiretroviral drugs in inhibiting OCT2 and their different abilities to modulate dolutegravir exposure, and considering the possibility of a direct independent neurotoxic effect, antiretroviral drugs used in combination with dolutegravir were also considered as potential confounder variables in multivariate models that included OCT2-encoding gene variant and/or dolutegravir C trough .
Results
Characteristics of study population
A cohort of 203 patients was analysed. Of these, 71.4% were male, and the median age was 51 years (IQR 43-57). The most common risk factors for HIV acquisition were heterosexual (44.8%) or homosexual (45.3%) contacts. Median time since HIV diagnosis was 13 years (IQR 5-21), with 11 years (IQR 4-18) of median exposure to ART and a median time on dolutegravir of 18 months (IQR 10-25). At the time of blood sampling for OCT2-encoding gene typing and dolutegravir plasma level determination, dolutegravir had been administered with lamivudine in 79 cases (38.9%), with abacavir/lamivudine in 72 (35.5%), tenofovir disoproxil fumarate/emtricitabine in 25 (12.3%), other potential OCT2 inhibitors, rilpivirine and cobicistat, in 9 (4.4%) and other antiretroviral drugs in 18 (8.9%). Most patients (97.5%) had a plasma HIV-RNA ,50 copies/mL. A current psychiatric disease, as defined by the assumption of specific drug therapy, was present in 6 (3.0%) patients. Characteristics of the study population are summarized in Table 1 .
Considering the SLC22A2 808 C ! A SNP, our population was mainly composed of CC homozygotes and no patient was carrying the homozygous AA genotype. There were 31 (15.3%) SLC22A2 808 CA genotype carriers (heterozygotes). Compared with CC genotype carriers, they presented an APD at dolutegravir start more often (9.7% and 1.8% of persons with psychiatric disease had the CA and CC genotype, respectively; P " 0.048), but no statistically significant differences were found according to sex and other clinical characteristics.
Median dolutegravir C trough was 1492 ng/mL (IQR 981-2234). Gender differences in dolutegravir C trough were statistically significant (P " 0.001); females with heterosexual intercourse as risk factor for HIV transmission had higher dolutegravir C trough (median concentration 1918 ng/mL; IQR 1193-2918) compared with heterosexual males (1509 ng/mL; 1071-2269), MSM (1319 ng/mL; IQR 877-1968), male intravenous drug users (IDUs, 825 ng/mL; IQR 469-1505) and female IDUs (1344 ng/mL; IQR 383-2898). No difference in dolutegravir C trough emerged among patients younger or older than 51 years (1513 and 1373 ng/mL respectively; P " 0.889) or among different antiretroviral combinations (P " 0.837); median value was 1380 ng/mL (IQR 955-2424) with abacavir/lamivudine, 954 ng/mL (IQR 631-2600) with rilpivirine or cobicistat-boosted darunavir, 1521 ng/mL (IQR 976-2176) with tenofovir disoproxil fumarate/emtricitabine and 1492 ng/mL (IQR 1071-2221) with lamivudine only.
NPs, dolutegravir concentration and SLC22A2 genotyping results
According to the SCL-90-R a pathological GSI score was present in 35 (17.2%) individuals. Concerning single dimensions, a somatization disorder was present in 61 (30.0%) persons, obsessive-compulsive disorder in 56 (27.6%), pathological interpersonal sensitivity in 26 (12.8%), depression in 51 (25.1%), anxiety and hostility in 38 (18.7%) each, phobic anxiety in 10 (4.9%), paranoid ideation in 38 (18.7%), psychoticism in 22 (10.8%) and sleep disorders in 96 (47.3%). Using the self-reported symptoms questionnaire, a moderate to severe headache in the preceding 4 weeks was reported by 14/201 (7.0%). Importantly, 15/199 (7.5%) reported suicidal ideation in the previous 2 weeks, and 2/199 patients (1.0%) also attempted to commit suicide in the previous month.
Associations of SLC22A2 gene polymorphism and dolutegravir C trough with NPs
Prevalence of SLC22A2 CA genotype compared with CC was higher in patients showing an abnormal GSI (32.3% versus 14.6%; P " 0.035), anxiety (35.5% versus 15.8%; P " 0.022), hostility (32.3% versus 16.4%; P " 0.047) and moderate to severe headache (16.7% versus 5.3%; P " 0.041). Considering neuropsychiatric scores as continuous variables, CA genotype carriers, compared with CC carriers, had higher median values of GSI (0.5 versus 0.4; SLC22A2 variants, DTG C trough and psychiatric symptoms JAC P " 0.075), anxiety (0.4 versus 0.2; P " 0.057) and hostility (0.7 versus 0.3; P " 0.080), as shown in Figure 1 . Higher median dolutegravir C trough was observed in patients with hostility (2019 versus 1344 ng/mL; P , 0.001) and psychoticism (2138 versus 1383 ng/mL; P " 0.003). No association of SLC22A2 genotypes and dolutegravir C trough emerged with the other neuropsychiatric dimensions, or with suicide attempts and suicide ideation. In multivariate analysis, CA genotype confirmed its independent association with an abnormal GSI [versus CC, adjusted OR (aOR) 2.43; P " 0.072; Table 2 ], anxiety (aOR 2.61; P " 0.044; Table 3 ) and hostility (aOR 3.76; P " 0.012; Table 4), as well as with an increased risk of self-reported moderate to severe headache during the last 4 weeks (aOR 5.55; P " 0.037; Table 5 ); conversely, SLC22A2 808 C ! A polymorphism was not independently associated with depression or with obsessive-compulsive disorder, after adjusting for confounders and other competing variables. Dolutegravir concentration showed an independent, dosedependent association with both hostility (third versus first quartile aOR 5.26; P " 0.021; fourth versus first quartile aOR 6.70; P " 0.007; Table 4 ) and psychoticism (third versus first quartile aOR 9.77; P " 0.047; fourth versus first quartile aOR 19.01; P " 0.008; Table 6 ).
As expected, APD was an independent risk factor for abnormal GSI (aOR 18.22; P " 0.011; Table 2), anxiety (aOR 15.32; P " 0.017; Table 3 ) and moderate to severe headache (aOR 7.76; P " 0.047; Table 5 ), but not for hostility or psychoticism. Concomitant antiretroviral drugs were also associated with increased risk of psychoticism (Table 6 ); compared with lamivudine plus dolutegravir, psychoticism was more frequent with both abacavir/lamivudine (aOR 5.40; P " 0.018), tenofovir disoproxil fumarate/emtricitabine (aOR 9.46; P " 0.006) and rilpivirine or cobicistat-boosted darunavir (aOR 13.33; P " 0.024). Gender was not associated with any NPs, whereas age was only associated with hostility; in contrast to our expectations, older age was a protective factor (per 10 years older, aOR 0.56; P " 0.007; Table 4 ). Despite adjusting for confounders, in order to exclude bias arising from unrecognized population stratification and any possible confounding effect of pre-existing psychiatric disorder on the outcomes, regression analysis was repeated after excluding non-Caucasian patients and patients with APD. In multivariate analysis, associations emerged between CA genotype and GSI (aOR 2.60; P " 0.068), anxiety (aOR 2.82; P " 0.039), hostility (aOR 3.92; P " 0.016) and moderate to severe headache (aOR 7.47; P " 0.029). Dolutegravir concentration also confirmed its association with hostility (third versus first quartile aOR 6.82; P " 0.024; fourth versus first quartile aOR 7.70; P " 0.014) and psychoticism (third versus first quartile aOR 8.26; P " 0.070; fourth versus first quartile aOR 14.42; P " 0.019).
In linear regression analysis, similar results emerged after adjusting for the same variables as for logistic regression. Considering the whole population, CA genotype was independently associated with an increased GSI score (versus CC, B: !0.17; P " 0.075) and increased hostility value (versus CC, B: !0.31; P " 0.006), but not with increased anxiety; increased scores for hostility and psychoticism were also associated with increased dolutegravir C trough (per 100 ng/mL higher, B: !0.01; P " 0.090, and B: !0.01; P " 0.080, respectively). When excluding non-Caucasian patients and individuals with pre-existing NPs, CA genotype was found to be more strongly associated with both GSI (versus CC, B: !0.22; P " 0.032) and hostility (versus CC, B: !0.39; P " 0.002) but also with anxiety (versus CC, B: !0.22; P " 0.067). Conversely, in the same subset of patients, less robust evidence emerged against the null hypothesis of no associations between dolutegravir C trough and both hostility (per 100 ng/mL more, B: !0.01; P " 0.099) and psychoticism (per 100 ng/mL more, B: !0.01; P " 0.130).
Discussion
Dolutegravir is recommended in different antiretroviral combinations for both treatment-naive and -experienced patients, 2,3 but a potential neuropsychiatric effect emerged in post-marketing studies, particularly affecting specific subgroups of patients, such as older patients and women. 8, 9 In this cohort of HIV-infected patients treated with different dolutegravir-containing antiretroviral regimens, an independent association of the SLC22A2 808 C ! A polymorphism and of higher dolutegravir C trough with increased risk of reporting NPs emerged.
SLC22A2 808 C ! A is a non-synonymous variant at position 270 that results in a single amino acid change from a serine to an alanine. It is present in a common unambiguous haplotype (haplotypes *3D and *3E) and has a particularly high allele frequency over all populations (12.7%). In vitro, this variant has a weak effect on transporter function: it exhibits an increase in the K m value of the prototypical organic cation MPP!, and a significant increase in the K i value of tetrabutylammonium is reported when expressed in Xenopus laevis oocytes. Furthermore, it could affect drug response by altering the renal elimination of xenobiotics in vivo. 25 Shin et al. 26 performed a genome-wide association study to investigate how genetic variations affect metabolism and diseases; the Borghetti et al.
authors reported the relationship of several metabolic loci and their biochemical connectivity with blood metabolites; the SLC22A2 808 SNP was found to be associated with the X-12798 metabolite. It is worth noting that no association was found between the carriage of the SLC22A2 808 (rs316019) C ! A polymorphism and dolutegravir pharmacokinetic exposure. CA genotype carriers were at higher risk of having an abnormal GSI; in particular they were more likely to report pathological scores of anxiety and hostility, as well as moderate to severe headache in the last 4 weeks prior to completing the questionnaire. Increasing dolutegravir plasma levels were also independently and dose-dependently associated with higher hostility risk and with psychoticism (a continuum of disorders ranging from mild interpersonal estrangement to overt psychosis). At the same time, an influence of dolutegravir on other psychiatric symptoms, especially sleep disturbances and suicide ideation, did not emerge.
OCT2 is a polyspecific, low-affinity carrier for a variety of physiological compounds and xenobiotics in mammals, including catecholamine, serotonin and choline neurotransmitters. 27 In mouse experiments, OCT2, together with other subtypes of OCT, is widely expressed throughout the forebrain, especially in anatomical structures of the limbic system, and takes part in the postsynaptic reuptake of the extraneuronal neurotransmitters, especially catecholamines, that escape from the high-affinity transporters. 18 The monoaminergic pathways control fundamental physiological functions within the CNS; among others, serotonin has been implicated in the modulation of mood, aggression and sleep, whereas noradrenaline has been associated with arousal, mood and stress, and dopamine with the control of motor function, motivation and reward, mood and cognition. The role of OCT2 in modulating the response to stress in rodents has already been evidenced; 27 by decreasing extracellular monoamine concentrations, OCT2 inhibits the corticosterone release driven by the hypothalamic-pituitaryadrenocortical system, and this in turn reduces stress and depression-like behaviours. Polymorphisms of the OCT2-encoding gene have already been demonstrated to influence substrate transport activity 28, 29 and several drugs have been shown to have an inhibitory effect on OCT2, 30 with a relevant influence in various clinical contexts. An interesting hypothesis has therefore been made concerning the potential role of different variants of the OCT2-encoding gene or of several OCT2-inhibiting drugs in SLC22A2 variants, DTG C trough and psychiatric symptoms JAC enhancing vulnerability to repeated adverse events, leading to chronic stress. 27 In line with this background, we found that different SLC22A2 808 genotypes, as well as increasing plasma levels of dolutegravir, a known OCT2 inhibitor, were associated with several NPs in HIV-infected patients treated with dolutegravir. Particularly, the CA variant was associated with anxiety, and this could be explained by reduced OCT2 activity compared with the CC variant; as observed in depression paradigms in OCT2-deficient mice that resulted in insensitivity to long-term venlafaxine treatment, 20 the minor transport activity of CA compared with CC genotype carriers might trigger adaptive modifications of other neurotransmitter receptors over time, which in turn could lead to the expression of depressive symptoms such as anxiety.
An association with increased risk of hostility was found for both the SLC22A2 C ! A SNP and increasing dolutegravir C trough . An increase in the activity of the limbic system, specifically of the amygdala (following a reduction of cortical control), has already been implicated in the onset of aggressive behaviours and disinhibition in humans. 31 It is reasonable to hypothesize that interference with neurotransmitter uptake could explain the higher frequency of this symptom observed in this group.
In a previous study by Yagura et al., 15 increased median dolutegravir C trough was detected in Japanese HIV-1-infected persons reporting CNS symptoms (dizziness, headache, insomnia, restlessness and anxiety) compared with persons without those symptoms. Moreover, a recent European retrospective study 10 also showed higher median dolutegravir concentrations (1719 ng/mL) in patients who interrupted dolutegravir. In line with these reports, our findings are consistent with the hypothesis of a neuromodulating effect of dolutegravir, involving at least some of the analysed NPs.
Contrary to previous reports showing an association of older age with NPs during dolutegravir treatment, 9 in this series older age was associated with a reduced risk of reporting some of the psychiatric symptoms analysed, particularly hostility and paranoid ideation. However, in our population persons .60 years old, the group at higher risk in the previous reports, were under-represented, and dolutegravir plasma exposure was slightly lower in persons .51 years old compared with younger people, which may partly explain this apparent discrepancy. In addition, the NPs leading to dolutegravir discontinuation in the cited cohort (mainly insomnia and sleep disturbances) could have a different pathophysiological cause; indeed, sleep disturbances were not found to have any association with dolutegravir C trough or with the SLC22A2 SNP. Dolutegravir concentrations were higher in women than in men; higher rates of dolutegravir discontinuations in women as evidenced in previous studies could have been at least partly explained by its increased concentrations.
An interesting association was found between concomitant antiretrovirals and risk of psychoticism. Compared with lamivudinebased two-drug regimens, a greater risk of psychoticism was seen with patients on rilpivirine or cobicistat-boosted darunavir. Both drugs have a recognized inhibitory effect on OCT2, and this could have further increased the overall effect of dolutegravir; however, owing to the lack of comparative data about the effect of different combinations with dolutegravir on the risk of neuropsychiatric Borghetti et al.
symptoms, this hypothesis needs to be further explored. The combination abacavir/lamivudine also increased the risk of psychoticism and was independent of dolutegravir concentrations. In a previous report 8 abacavir was associated with a higher risk of dolutegravir discontinuation, possibly resulting from competition for a metabolic step the two drugs have in common (glucuronidation) leading to higher pharmacokinetic exposure of dolutegravir. However, in our series patients on abacavir/lamivudine had lower dolutegravir concentrations compared with those receiving other NRTI combinations; moreover, the effect of abacavir/lamivudine exposure on psychoticism was independent of dolutegravir C trough . Unexpectedly, the concomitant use of tenofovir disoproxil fumarate/emtricitabine was also associated with psychoticism. While both emtricitabine and lamivudine are substrates but not inhibitors of OCT2, data on the effect of tenofovir disoproxil fumarate on OCTs are conflicting; 32, 33 however, owing to the paucity of data concerning possible neuropsychiatric effects of tenofovir and emtricitabine, 34 a direct neurotoxicity of these compounds appears unlikely. Although an interference with OCT2 or other mediators of brain function could not be completely excluded, other unmeasured confounders could explain our findings, which therefore need further confirmation.
Our study suffers from some important limitations that have to be acknowledged. Firstly, this is a cross-sectional analysis that did not take into consideration a validated neuropsychiatric evaluation at the time of dolutegravir start and therefore could not assess whether psychiatric symptoms were already present before dolutegravir; also, the lack of a comparison arm to investigate potential differences in psychiatric symptom onset makes it difficult to ascertain the unique role of dolutegravir in determining these alterations and firmly establishing a cause-effect relationship. Moreover, patients recruited here were on a stable dolutegravir regimen, which represents a selection bias that excluded from our analysis individuals discontinuing dolutegravir owing to side effects. Finally, caution in interpreting our results is needed also owing to the lack of an increased rate of neuropsychiatric events in studies investigating the use of dolutegravir twice daily, 35, 36 in which patients could have presented much higher dolutegravir concentrations. However, it should be noticed that the polymorphisms in SLC22A2 gene were not evaluated in previous dolutegravir studies, and therefore their prevalence and impact are not known; more importantly, the limited therapeutic possibilities for patients enrolled in studies with dolutegravir twice daily could have played a deterrent role in discontinuing dolutegravir for only mild or moderate NPs, which have not been systematically investigated. Indeed, one important strength of our study is that it represents the first attempt to systematically investigate specific neuropsychiatric symptoms with a validated questionnaire, as well as with a psychiatric interview by a specialist neuropsychologist and a selfreported questionnaire, in HIV-1-infected individuals during dolutegravir therapy. Compared with a previous study 15 on this subject, we also extended its results to a larger, Western European population. Moreover, a molecular pathophysiological mechanism underlying neuropsychiatric effects of dolutegravir is postulated here for the first time, and our results give an insight that prompts SLC22A2 variants, DTG C trough and psychiatric symptoms JAC further investigation; if confirmed by prospective studies, determination of variants of the OCT2-encoding gene and therapeutic drug monitoring of dolutegravir could become important tools to support treatment choices and monitoring. Given the widespread use of dolutegravir in clinical practice, further studies aiming to determine the predictors and clinical relevance of the neuropsychiatric side effect of this drug are needed.
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